Strategic partnerships Fina Biosolutions already licenses its conjugation and carrier protein technology to major vaccine manufacturers in Europe and Asia, including GSK and Serum Institute of India. This indicates a strong pathway for collaboration and co-development with large players or tiered licensing deals to expand market reach.

Conjugate vaccine expertise The company specializes in novel conjugation, purification, and manufacturing of complex vaccine conjugates and CRM197 carrier proteins, presenting opportunities to sell custom conjugation services, carrier proteins, or contract development/manufacturing (CDMO) partnerships to vaccine developers aiming to accelerate time to market.

Growing funding With recent investments and a revenue range of one to ten million dollars plus a three million dollar funding round, there is notable growth traction and potential for scale-up collaborations, co-development programs, or milestone-based licensing deals with higher-resource partners.

Global market access Current international licensing and collaborations suggest readiness to engage distributors, contract manufacturers, and regional partners across Europe, Asia, and the U.S. to expand adoption of CRM197-based carriers and conjugation technology into new vaccine portfolios.

cdmo and supply stability Recent production partnerships for cGMP CRM197 and carrier proteins point to reliable manufacturing capabilities; this can be leveraged to offer ongoing manufacturing services, supply agreements, or capacity commitments to vaccine developers seeking stable, compliant production partners.